Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$34.4 million.

  • Century Therapeutics' Net Income towards Common Stockholders fell 1023.51% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.5 million, marking a year-over-year increase of 7961.75%. This contributed to the annual value of -$126.6 million for FY2024, which is 739.71% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Net Income towards Common Stockholders is -$34.4 million, which was down 1023.51% from -$32.5 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Net Income towards Common Stockholders registered a high of $76.6 million during Q1 2025, and its lowest value of -$39.4 million during Q4 2023.
  • Over the past 4 years, Century Therapeutics' median Net Income towards Common Stockholders value was -$31.7 million (recorded in 2022), while the average stood at -$25.6 million.
  • Per our database at Business Quant, Century Therapeutics' Net Income towards Common Stockholders crashed by 2436.4% in 2023 and then skyrocketed by 37282.45% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Net Income towards Common Stockholders stood at -$31.7 million in 2022, then fell by 24.36% to -$39.4 million in 2023, then grew by 8.45% to -$36.1 million in 2024, then grew by 4.58% to -$34.4 million in 2025.
  • Its last three reported values are -$34.4 million in Q3 2025, -$32.5 million for Q2 2025, and $76.6 million during Q1 2025.